Logo

ENTA

Enanta Pharmaceuticals, Inc.

ENTA

Enanta Pharmaceuticals, Inc. • NASDAQ
$14.12 ▲ 1.29% (+0.18)
Market Cap $301.23 M
52w High $15.34
52w Low $4.09
Dividend Yield 0%
P/E -3.68
Volume 123.55K
Outstanding Shares 21.33M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2025 $15.125M ▼ $33.511M ▼ $-18.7M ▼ -123.636% ▼ $-0.87 ▼ $-16.281M ▼
Q3-2025 $18.314M ▲ $37.207M ▼ $-18.255M ▲ -99.678% ▲ $-0.85 ▲ $-15.398M ▲
Q2-2025 $14.926M ▼ $39.453M ▼ $-22.644M ▼ -151.708% ▼ $-1.06 ▼ $-21.032M ▼
Q1-2025 $16.959M ▲ $40.502M ▼ $-22.29M ▲ -131.435% ▲ $-1.05 ▲ $-19.855M ▲
Q4-2024 $14.607M $44.461M $-28.823M -197.323% $-1.36 $-26.126M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2025 $188.864M ▼ $280.732M ▼ $216.015M ▼ $64.717M ▼
Q3-2025 $204.111M ▲ $301.029M ▼ $221.75M ▼ $79.279M ▼
Q2-2025 $193.375M ▼ $322.993M ▼ $229.455M ▼ $93.538M ▼
Q1-2025 $216.691M ▼ $348.642M ▼ $236.826M ▼ $111.816M ▼
Q4-2024 $248.186M $376.652M $247.838M $128.814M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-18.255M ▲ $17.506M ▲ $-26.483M ▼ $-6.424M ▲ $-15.401M ▲ $17.351M ▲
Q2-2025 $-22.644M ▼ $-13.488M ▲ $-4.369M ▼ $-6.887M ▼ $-24.744M ▼ $-16.026M ▲
Q1-2025 $-22.29M ▲ $-16.801M ▼ $68.903M ▲ $-4.986M ▲ $47.116M ▲ $-25.546M ▼
Q4-2024 $-28.823M ▼ $-10.4M ▲ $19.073M ▲ $-7.215M ▼ $1.458M ▲ $-19.351M ▲
Q3-2024 $-22.658M $-14.775M $-6.345M $-6.647M $-27.767M $-21.317M

Revenue by Products

Product Q1-2025Q2-2025Q3-2025Q4-2025
Royalty
Royalty
 $20.00M ▲$10.00M ▼$20.00M ▲$20.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Enanta’s income statement reflects a classic development‑stage biotech profile: small and slowly declining revenue, likely tied to maturing royalty streams, and consistently sizable operating losses. The company’s core business is still research and development rather than product sales, so expenses meaningfully exceed income. Losses per share have deepened over time, suggesting that without new commercial products or large partnership payments, profitability remains a distant prospect. Overall, the P&L shows a company investing heavily today in hopes of future drug approvals, with current revenue streams too small to offset its R&D and operating costs.

Balance Sheet

Balance Sheet The balance sheet shows a gradual erosion of equity over the past few years, reflecting cumulative losses. Cash levels have come down from prior years, while debt has risen recently, shifting the capital structure toward more leverage and less cushion. Total assets have drifted lower, which is common when a biotech spends down cash to fund trials. While management and external commentary suggest a multi‑year cash runway, the trend is clearly one of drawing on the balance sheet to pay for ongoing development, making future access to capital and careful spending discipline important watchpoints.

Cash Flow

Cash Flow Cash flow is consistently negative from operations, meaning the business consumes cash rather than generates it. Free cash flow is also negative year after year, and while capital spending is modest, it still adds to the cash burn. This pattern is typical for a biotech without marketed products, but it underscores reliance on existing cash, potential partnerships, grants, or future financing to keep the pipeline moving. The key question is whether upcoming clinical milestones will arrive before the cash burn forces difficult funding or prioritization decisions.

Competitive Edge

Competitive Edge Enanta occupies a focused niche in small‑molecule antivirals, with a credible track record from its hepatitis C discoveries that are used in AbbVie’s therapies. Those historical successes give it scientific credibility and some royalty backing, but the commercial tail from HCV is likely shrinking, and competition in antivirals and immunology is intense, especially from much larger pharmaceutical companies. Its emerging strength is a concentrated push into respiratory viruses—especially RSV—and a selective expansion into immunology, where differentiated oral drugs could stand out against injectable biologics. However, the company’s overall competitive position still hinges on converting its pipeline into approved products or valuable partnerships; until then, it remains a smaller specialist competing in markets dominated by bigger players with deeper pockets.

Innovation and R&D

Innovation and R&D Innovation is the clear centerpiece of Enanta’s story. The company has strong medicinal chemistry capabilities and a history of translating that into real-world drugs, which is more than many small biotechs can claim. Its RSV program is particularly important, with two different types of inhibitors that could allow combination approaches and broader treatment options if trials succeed. At the same time, Enanta is deliberately pivoting beyond antivirals into immunology, targeting mast cell–driven diseases and atopic dermatitis with oral small molecules. This diversification could open larger, more durable markets, but it also raises execution risk, as the company moves into crowded, heavily studied disease areas. Overall, R&D productivity looks promising, but the pipeline is still in development, and scientific as well as regulatory setbacks are an ongoing risk.

Summary

Enanta is a science‑driven biotech with a solid track record in antivirals and a pipeline that now spans both respiratory viruses and immunology. Financially, it remains in an investment and cash‑burn phase, with modest royalty-driven revenue, persistent losses, and a balance sheet that has leaned more on existing cash and some debt over time. The company’s value proposition rests on turning its RSV and immunology candidates into successful late‑stage programs and, ultimately, commercial products or partnerships. Investors following Enanta will likely focus on clinical trial readouts, partnering activity, and the pace of cash use, as these will determine whether its innovative pipeline can translate into a more durable and self-sustaining business over the next several years.

NEWS

November 17, 2025 · 4:01 PM UTC

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025

Read more

November 4, 2025 · 7:00 AM UTC

Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences

Read more

October 20, 2025 · 7:00 AM UTC

Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025

Read more

October 7, 2025 · 7:00 AM UTC

Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025

Read more

October 2, 2025 · 4:01 PM UTC

Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Read more